Literature DB >> 9881504

Irritable bowel syndrome symptom patterns: frequency, duration, and severity.

B Hahn1, M Watson, S Yan, D Gunput, J Heuijerjans.   

Abstract

We examined symptom frequency, duration, and severity, as well as episode patterns, in 122 adult patients with irritable bowel syndrome in a 12-week study conducted in the United States, the United Kingdom, and The Netherlands. Patients used an interactive telephone data entry system daily to report symptoms. Data from 59 of the patients meeting inclusion criteria are presented, the remainder having been excluded for failing to complete at least 70 days of symptom reporting. The majority of patients experienced at least one symptom on over 50% of the reported days; however, individual symptoms were reported on less than 50% of the days, indicating that symptoms sometimes occurred sequentially rather than always simultaneously. On average, patients reported pain/discomfort on 33% of days, bloating on 28% of the days, altered stool form or stool passage on 25% and 18% of the days, respectively, and mucus on 7% of the days. The duration of symptoms was relatively short, with pain/discomfort and bloating lasting the longest, an average of five days each per episode. All symptoms but one (mucus) were moderately severe on the majority of reported days. Patients experienced an "episode" (defined as a period of days with symptoms bounded by one or more symptom-free days) on an average of 12.4 times during the study, but the duration of these episodes varied greatly among patients. These results further establish the chronic nature of irritable bowel syndrome and the burden that this condition imposes on patients.

Entities:  

Mesh:

Year:  1998        PMID: 9881504     DOI: 10.1023/a:1026663613695

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  9 in total

1.  The short-term natural history of irritable bowel syndrome: a time-series analysis.

Authors:  J A Stevens; C K Wan; E B Blanchard
Journal:  Behav Res Ther       Date:  1997-04

Review 2.  The irritable bowel syndrome: review and a graduated multicomponent treatment approach.

Authors:  D A Drossman; W G Thompson
Journal:  Ann Intern Med       Date:  1992-06-15       Impact factor: 25.391

Review 3.  The irritable bowel syndrome: mechanisms and a practical approach to management.

Authors:  M Camilleri; C M Prather
Journal:  Ann Intern Med       Date:  1992-06-15       Impact factor: 25.391

4.  Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life.

Authors:  B A Hahn; L J Kirchdoerfer; S Fullerton; E Mayer
Journal:  Aliment Pharmacol Ther       Date:  1997-06       Impact factor: 8.171

Review 5.  What are functional bowel disorders?

Authors:  J Zighelboim; N J Talley
Journal:  Gastroenterology       Date:  1993-04       Impact factor: 22.682

Review 6.  Irritable bowel syndrome.

Authors:  R B Lynn; L S Friedman
Journal:  N Engl J Med       Date:  1993-12-23       Impact factor: 91.245

7.  Epidemiology of irritable bowel syndrome in the United States.

Authors:  R S Sandler
Journal:  Gastroenterology       Date:  1990-08       Impact factor: 22.682

Review 8.  Irritable bowel syndrome: pathogenesis and management.

Authors:  W G Thompson
Journal:  Lancet       Date:  1993-06-19       Impact factor: 79.321

9.  Towards a better understanding of patients with irritable bowel syndrome.

Authors:  C P Dancey; S Backhouse
Journal:  J Adv Nurs       Date:  1993-09       Impact factor: 3.187

  9 in total
  16 in total

Review 1.  Expert commentary--bloating, distension, and the irritable bowel syndrome.

Authors:  Richard Lea; Peter J Whorwell
Journal:  MedGenMed       Date:  2005-01-10

2.  Gas and Bloating.

Authors:  William L Hasler
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-09

3.  Acute exacerbation of pain in irritable bowel syndrome: efficacy of phloroglucinol/trimethylphloroglucinol. A randomized, double-blind, placebo-controlled study.

Authors:  O Chassany; B Bonaz; S Bruley DES Varannes; L Bueno; G Cargill; B Coffin; P Ducrotté; V Grangé
Journal:  Aliment Pharmacol Ther       Date:  2007-05-01       Impact factor: 8.171

Review 4.  Costs of irritable bowel syndrome in the UK and US.

Authors:  Stefanie Maxion-Bergemann; Frank Thielecke; Florian Abel; Rito Bergemann
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

5.  A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.

Authors:  J Tack; S Müller-Lissner; P Bytzer; R Corinaldesi; L Chang; A Viegas; S Schnekenbuehl; C Dunger-Baldauf; P Rueegg
Journal:  Gut       Date:  2005-07-14       Impact factor: 23.059

Review 6.  Benefit-risk assessment of tegaserod in irritable bowel syndrome.

Authors:  Richard Lea; Peter J Whorwell
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

7.  Insights into normal and disordered bowel habits from bowel diaries.

Authors:  Adil E Bharucha; Barbara M Seide; Alan R Zinsmeister; L Joseph Melton
Journal:  Am J Gastroenterol       Date:  2007-11-16       Impact factor: 10.864

8.  Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome.

Authors:  Lawrence A Szarka; Michael Camilleri; Duane Burton; Jean C Fox; Sanna McKinzie; Timothy Stanislav; Julie Simonson; Nancy Sullivan; Alan R Zinsmeister
Journal:  Clin Gastroenterol Hepatol       Date:  2007-09-27       Impact factor: 11.382

Review 9.  Role of negative affects in pathophysiology and clinical expression of irritable bowel syndrome.

Authors:  Maria Rosaria A Muscatello; Antonio Bruno; Giuseppe Scimeca; Gianluca Pandolfo; Rocco A Zoccali
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

Review 10.  Guidelines on the irritable bowel syndrome: mechanisms and practical management.

Authors:  R Spiller; Q Aziz; F Creed; A Emmanuel; L Houghton; P Hungin; R Jones; D Kumar; G Rubin; N Trudgill; P Whorwell
Journal:  Gut       Date:  2007-05-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.